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Abstract  26 
 27 
The ATP-sensitive homomeric P2X7 receptor (P2X7R) has received particular 28 
attention as a potential drug target because of its widespread involvement in 29 
inflammatory diseases as a key regulatory element of the inflammasome 30 
complex. However, it has only recently become evident that P2X7Rs also play a 31 
pivotal role in central nervous system (CNS) pathology. There is an explosion of 32 
data indicating that genetic deletion and pharmacological blockade of P2X7Rs 33 
alter responsiveness in animal models of neurological disorders, such as stroke, 34 
neurotrauma, epilepsy, neuropathic pain, multiple sclerosis, amyotrophic 35 
lateralsclerosis, Alzheimer’s disease, Parkinson’s disease, and Huntington’s 36 
disease. Moreover, recent studies suggest that P2X7Rs regulate the 37 
pathophysiology of psychiatric disorders, including mood disorders, implicating 38 
P2X7Rs as drug targets in a variety of CNS pathology.  39 
 40 
 41 
  42 
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It has been known for almost a decade that P2X7Rs convey important 43 
physiopathological functions in the CNS [1]. The aim and scope of the present 44 
review are to summarize the latest developments in the description of these 45 
functions, to redirect interest to those fields, where there are still significant gaps 46 
in our present understanding and to promote further development of those 47 
therapeutic areas, in which P2X7R is the most promising as a potential drug 48 
target.  49 
  50 
The structure and molecular physiology of P2X7Rs  51 
 52 
P2X7Rs are ATP-gated, non-selective cation channels belonging to the family of 53 
ionotropic P2X receptors. P2X7Rs function in homo-trimeric form and most 54 
mammalian P2X7R subunits comprise 595 amino acids [2]. The common 55 
structural motifs of P2X7Rs are the two transmembrane domains (TM1, TM2), a 56 
large, glycosylated, cysteine-rich extracellular loop, a short intracellular N-57 
terminal domain, and an intracellular C-terminal domain, which is longer than that 58 
of other P2X receptor subunits. Within the family of P2X receptors, so far only the 59 
crystal structure of zebrafish (zf)P2X4.1R has been solved in the closed [3] and 60 
ATP-binding, open state [4]; nevertheless, its considerable homology with 61 
mammalian P2X7Rs allowed for the structural modelling of the latter [2]. The 62 
molecular architecture of an individual P2X7R subunit is akin to a leaping 63 
dolphin, with the extracellular loop forming the body, and the TM domains 64 
forming the tail. When co-assembled as a trimeric unit, P2X7R has a chalice-like 65 
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structure, overarching the channel pore (Figure 1A). There are three ATP binding 66 
sites localized at the interface of the three subunits; occupancy of at least two of 67 
the three sites is necessary for the activation of the receptors [5]. The adenine 68 
base and the - and -phosphate groups of ATP form hydrogen bonds with the 69 
respective amino acid residues of the ATP binding pocket, as suggested for the 70 
zfP2X4.1R. However, because a residue corresponding to Leu217, which 71 
interacts with the ribose moiety, is missing in the mammalian P2X7R, the affinity 72 
of ATP to P2X7Rs is more than a hundredfold lower than to other P2XR-73 
subtypes [2]. On the other hand, non-conserved residues surrounding the ATP 74 
binding site might confer differences in agonist sensitivity between mammalian 75 
P2XR species, (i.e. rat P2X7Rs display substantially higher sensitivity to ATP and 76 
BzATP than their human and mouse counterparts [6]). A distinctive feature of the 77 
mouse P2X7R is that it can be activated by extracellular nicotinamide adenine 78 
dinucleotide (NAD+) by ADP-ribosylation with the ADP-ribosyltransferase 2 79 
ectoenzyme [7]. In contrast, less is known about the binding site of antagonists, 80 
although potent and selective antagonists of P2X7Rs are now widely available. 81 
Earlier data indicated that P2X7R subunits are able to form heterotrimers with 82 
P2X4Rs [8], but more recent studies did not confirm this (e.g. [9]). 83 
   There are several splice variants of mammalian P2X7Rs, all of which are 84 
widely expressed in the nervous system. Hence, a naturally occurring truncated 85 
isoform of the human P2X7R (P2X7B) has been found  in the CNS [10]; a C-86 
terminally truncated variant of mouse P2X7R has also been identified, which 87 
partly retains its functionality, when expressed in tissues of the P2rx7 gene 88 
5 
 
deficient mice [11]. Another mouse isoform is the P2X7(k) variant, which in 89 
contrast to P2X7(a), is sensitive to ADP-ribosylation [12, 13].  90 
   The gene encoding the human P2X7R (P2RX7) is also well known to exhibit a 91 
number of non-synonymous single nucleotide polymorphisms (NS-SNPs), which 92 
results in a change in amino acid sequence and the expression of different 93 
human P2X7 variants, further increasing the structural diversity of P2X7Rs. The 94 
functional consequence of several individual NS-SNPs has been determined in 95 
native and recombinant systems and their association with various human CNS 96 
disease states has been extensively investigated in genetic linkage studies [14]. 97 
   The activation of P2X7Rs results in the opening of the channel pore, allowing 98 
the passage of small cations (Na+, Ca2+, and K+). In addition, a hallmark feature 99 
of the P2X7R is the opening of a non-selective pore in response to repeated or 100 
prolonged activation, allowing the permeation of large molecular weight organic 101 
cations up to 600-800 Da. The pore forming property of P2X7Rs can be studied 102 
by the uptake of high molecular weight cations, such as NMDG+, or dyes, such 103 
as Yo-Pro-1 or ethidium bromide; nevertheless, its molecular mechanism has 104 
remained a highly debated issue, with two alternative, but non excluding 105 
possibilities, both having substantial experimental support (Figure 1 B, C). The 106 
first potential mechanism is the progressive dilation of the P2X7R-gated channel 107 
itself.  A conformational change of the receptor-protein could be the structural 108 
basis for channel dilation, as previously confirmed for other P2XRs (P2X2, P2X4) 109 
by electrophysiological methods [15]. In agreement with the pore dilation theory, 110 
the carboxyl terminal domain [16] and the TM2 region of the P2X7R protein are 111 
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essential for pore formation [17]. Moreover, recent studies revealed that the open 112 
channel conformation of the P2X7R can allow the passage of negatively charged 113 
fluorescent dyes with molecular diameters of  up to 1.4 nm [18], and occupation 114 
of one or two agonist binding sites favors transition to the desensitized state, 115 
whereas occupation of the third binding site favors the transition to the 116 
sensitized/dilated state [19].  117 
   The alternative mechanism involves the recruitment of an additional pore-118 
forming protein, most likely the pannexin-1 hemichannel (Panx1). Evidence 119 
derived from studies using genetic knockdown of Panx1 indicate that this protein 120 
is indispensable for the pore formation (e.g. [20]) and can be selectively affected 121 
pharmacologically by colhicine [21]. However, other data conflict with the 122 
involvement of Panx1 in the formation of the membrane pore (e.g. [22]). 123 
Therefore, it appears that although recruitment of pannexin hemichannels is a 124 
downstream signaling event closely linked to P2X7R activation, it is not an 125 
absolute requirement [23]. A potential dissolution of  conflicting results is that 126 
different P2X7R splice variants display distinct pore forming properties  [12, 23]. 127 
   The opening of the large pore might eventually result in membrane blebbing 128 
and cell death; however, this is not an obligatory consequence of P2X7R 129 
activation. Pore formation might gain significance in the pathological sensitization 130 
underlying chronic pain as highlighted by a recent study [24]. This paper reported 131 
that mutations of the gene encoding the P2X7R, which result in hypofunctional 132 
pore formation, affect chronic pain sensitivity in both mice and humans. Moreover 133 
treatment with a peptide corresponding to the P2X7R C-terminal domain, which 134 
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blocks pore formation, but not cation channel activity, selectively reduced 135 
allodynia only in mice with the pore-forming P2rx7 allele. These findings illustrate 136 
that the pore formation associated with P2X7R, by itself could be a potential 137 
target of personalized therapy to combat chronic pain disorders.  138 
    139 
Tissue and cell type specific distribution of P2X7Rs  140 
 141 
P2X7Rs are expressed by many cell types, including cells of hematopoietic origin 142 
(lymphocytes, monocyte-macrophages, microglia) and intrinsic cells of the 143 
nervous system (neurons, astrocytes, oligodendrocytes, Schwann cells). P2X7R 144 
binding sites have been explored in autoradiographic studies using the 145 
radioligand [³H]-A-804598, and a dense P2X7R binding was found throughout the 146 
brain and spinal cord [25], including hypothalamic nuclei, thalamic nuclei, 147 
hippocampus, spinal trigeminal nucleus and tract, cortical regions, cerebellum 148 
and caudate putamen [25]. Nevertheless, the cell-type specific localization of the 149 
P2X7Rs in the CNS has been the subject of a long-standing debate, which has 150 
not reached general consensus even after a decade: immunohistochemical 151 
findings are inhomogeneous and contradict findings obtained by physiological 152 
and neurochemical methods. Whereas early studies found a prominent 153 
expression of P2X7R immunoreactivity (IR) on excitatory nerve terminals [26], 154 
and later studies confirmed these findings throughout the CNS [27, 28]; other 155 
groups questioned these findings, revealing P2X7R-immunoreactivity in brain 156 
sections obtained from P2X7R deficient animals [29]. Subsequently however, 157 
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functional splice variants of rodent P2X7R [11, 12] were identified which are likely 158 
to be responsible for P2X7-pseudo-immunoreactivities, found in the brain of 159 
P2X7R-/- mice. These variants represent either gain- or loss-of function P2X7Rs, 160 
and may explain the high variability of responses induced by P2X7R stimulation. 161 
Other studies reported an activity-dependent expression pattern of P2X7Rs, 162 
induced or upregulated  following an insult such as a seizure [30], ischemia [31], 163 
sleep deprivation [32], undernourishment [33], or morphine tolerance [34]. A 164 
recent study utilizing single particle tracking photoactivated localization 165 
microscopy (sptPALM) revealed that Dendra2 tagged P2X7Rs transfected to 166 
hippocampal neurons formed two dynamic populations within the extrasynaptic 167 
membrane of proximal dendrites: one was composed of rapidly diffusing 168 
receptors and another stabilized within nanoclusters, both being rarely 169 
appositioned to synaptic sites [35].  170 
In contrast to immunohistochemistry, the available evidence on functional 171 
P2X7Rs on different cell types of the CNS is convincing. Functional studies, 172 
verifying P2X7Rs on neurons, astrocytes and microglia are presented in Table 1. 173 
The most parsimonious explanation for the contradictory findings is that the 174 
expression of P2X7Rs dynamically changes in response to experimental 175 
variables such as age or different levels of stressful stimuli prior to sample 176 
collection (freshly prepared vs. fixed sections). Moreover, under in vivo conditions 177 
even mild stimuli, such as saline injection, may cause a dramatic change in the 178 




Physiopathology of P2X7 receptors  181 
 182 
P2X7R function can be studied with a selection of pharmacological and genetic 183 
tools (Box 1). The activation of P2X7Rs is followed by Ca2+ influx and a variety of 184 
cellular responses depending on the cell type investigated (Figure 2). Outside the 185 
nervous system, the most prominent role of P2X7R is in the regulation of 186 
cytokine response to inflammatory challenge. In fact, P2X7R is a key regulatory 187 
element of the inflammasome molecular complex, providing the external stimulus 188 
necessary for the posttranslational modification and subsequent release of the 189 
pro-inflammatory cytokine IL-1. The role of P2X7Rs has been confirmed in the 190 
regulation of central cytokine response after LPS priming [36]. This effect could 191 
be involved in physiological and pathological actions controlled by P2X7Rs, such 192 
as memory formation [37]; sleep [32], fever [38], hyperalgesia [39] and 193 
depression [40, 41].  194 
However, a major caveat in our understanding of the physiopathology of 195 
P2X7R function is how the endogenous activation of P2X7Rs is achieved, given 196 
the low affinity of the endogenous agonist ATP. ATP is present in the synaptic 197 
vesicles and is co-released as a co-transmitter with various other transmitters in 198 
the autonomic nervous system under physiological conditions [42]. This holds 199 
also true to a certain extent for central synapses and the increase in extracellular 200 
ATP in response to normal neuronal activity might transiently reach the high 201 
micromolar concentration required for the activation of P2X7R, at least in the 202 
synaptic cleft. However, a more widespread activation of P2X7Rs is expected 203 
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under pathological conditions, when tissue damage, trauma or other pathological 204 
signals provide an ATP-rich extracellular milieu, which might lead to the 205 
activation of extrasynaptic and extraneuronal P2X7Rs. In addition, the possibility 206 
of constitutive activity without the presence of the endogenous agonist cannot be 207 
excluded either and should be further investigated. In the CNS, the best 208 
characterized consequence of P2X7R activation is the release of 209 
neurotransmitters, in particular of glutamate to the extracellular space [43]. This 210 
effect could be evoked both from synaptosomes [44] and from astrocytes [45]. In 211 
nerve terminals and cell lines expressing recombinant P2X7Rs, the P2X7R 212 
mediated glutamate release appears to be both exocytotic and non-exocytotic, 213 
[46, 47]. P2X7R mediated excitatory amino acid efflux can be detected in acutely 214 
prepared brain slices by neurochemical (e.g. [48, 49]) and electrophysiological 215 
techniques [50]. In rat hippocampal (hilar neurons; [51] CA1 neurons [52]), and 216 
midbrain slices (locus coeruleus; [50]), stimulation of P2X7Rs by BzATP elicited 217 
an increase of the frequency but not amplitude of spontaneous excitatory 218 
postsynaptic currents (sEPSCs) and miniature (m)EPSCs. Occasionally [49, 50] 219 
the P2X7R-mediated glutamate release was sensitive to blockade by fluorocitric 220 
acid, a glia-selective metabolic poison, and to antagonists of glutamate receptors. 221 
These findings imply that glutamate release induced by P2X7R stimulation from 222 
neurons could also be indirect, mediated by glutamate release from astrocytes, 223 
acting subsequently on glutamatergic nerve terminals. 224 
   To add further complexity to neuron-glia and glia-neuron P2X7R signaling, 225 
P2X7R stimulation elicits or reinforces the release of ATP, thereby providing an 226 
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auto-stimulatory loop. This effect was observed in retinal ganglion cells [53] 227 
hippocampal brain slices [49] and cultured spinal cord astrocytes [54]. The 228 
mechanism of P2X7R-driven ATP release could be exocytotic, as observed by 229 
total internal reflection microscopy in neuroblastoma cells [55], whereas in other 230 
studies it appears to involve connexin and/or pannexin hemichannels [49, 54].  231 
      A further interesting function of P2X7Rs is to regulate differentiation and cell-232 
fate during development. P2X7Rs are expressed by both embryonic [56] and 233 
adult neural progenitor cells (NPCs) in the subventricular zone of the lateral 234 
ventricle [57]. Whereas stimulation of P2X7Rs induces neuronal differentiation in 235 
embryonic NPCs [56], other studies indicated that P2X7Rs stimulate gliogenesis 236 
[58]. In contrast, the activation of P2X7Rs on adult, cultured NPCs decrease cell 237 
proliferation and induce necrotic/apoptotic cell death [57].  238 
   Of note, a very recent study showed that P2X7Rs regulate ion channel density 239 
and protein composition/function of the axon initial segment, a key structural 240 
element of neuronal excitability and in consequence action potential initiation in 241 
cultured hippocampal neurons and brain slices [59].  242 
It has been known for a long time that P2X7R activation might lead to cell death 243 
through pore formation as it has been described for peripheral immune cells. 244 
However, a more recently emerging view is that P2X7Rs also convey trophic 245 
function against cell-death promoting physiological or pathological stimuli: for 246 
example the microglial “suicide” P2X7R promotes cell cycle progression and 247 
proliferation [60, 61], and this receptor might act as a scavenger for the removal 248 




P2X7R as a potential target in neurological diseases  251 
 252 
ATP is released in large quantities following any kind of cell injury, and the 253 
ensuing stimulation of the low affinity P2X7R results in necrosis/apoptosis or 254 
proliferation as the two opposing end-points of neuroinflammation. P2X7R 255 
antagonists are potential therapeutics of traumatic brain injury, stroke, epilepsy, 256 
neuropathic pain, and neurodegenerative illnesses, because in these cases 257 
secondary cell damaging conditions accompany the primary pathological 258 
condition. 259 
Middle cerebral artery occlusion, the most widely used animal model of 260 
cerebral ischemia, results in cell death in the core of the affected neuronal tissue, 261 
while around it, in the so called penumbra, the cellular damage is reversible. Both 262 
infarct size and neurological deficits were reduced by P2X7R antagonists [64, 263 
65]. In combination with the sequential up-regulation of P2X7R-IR in microglia 264 
and then in astrocytes and neurons, this receptor-type was considered to be a 265 
primary target of the considerable amounts of ATP released. Similar results were 266 
reported for subarachnoid hemorrhage [66], traumatic brain [67, 68] or spinal 267 
cord injury [69] and ischemic retina degeneration [70]. However, a later study 268 
failed to reconfirm the protective action of P2X7R in spinal cord injury [71].  269 
Reperfusion after transient global cerebral ischemia exacerbates the 270 
consequences of oxygen/glucose deprivation (OGD) due to microglial and 271 
astroglial activation [72]. The ensuing neuroinflammatory reaction is also 272 
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alleviated by P2X7R antagonists [73, 74].     BBG partially reversed the OGD-273 
induced anoxic depolarization and cell damage in cultured oligodendrocyte cells 274 
[75]. Accordingly, left common carotid artery occlusion decreased P2X7R-275 
immunoreactivity at oligodendrocyte precursor cells in cerebral cortex, subcortical 276 
white matter and hippocampus [76].    277 
 Status epilepticus (SE)-like seizures, modelled in rodents by pilocarpine or 278 
kainate, up-regulate P2X7R-immunoreactivity in microglial cells [77] astrocytes 279 
and neurons [78]; quantification by western-blotting confirmed these results [79, 280 
80].  Utilizing the intra-amygdala application of kainate as an epileptic stimulus  281 
[79, 80], it was shown that (1) Bz-ATP facilitated and prolonged the EEG activity 282 
caused by seizures, and (2) P2X7R antagonists had a neuroprotective effect 283 
after epilepsy due to suppression of IL- production and microglial response. 284 
More recent findings suggest that the effect of P2X7Rs during SE depends on 285 
the nature of the chemical stimulus used. A-438079 decreased pilocarpin-286 
induced seizure susceptibility in mice by interrupting a direct facilitatory 287 
interaction between P2X7- and muscarinic receptors [81] or blockade of the 288 
release of the protective TNF- [82]. P2X7R activation also influenced leukocyte 289 
infiltration [83] and reactive astrogliosis following SE [84]. 290 
 The involvement of P2X7Rs in different models of inflammatory and 291 
neuropathic pain and the potential therapeutic effect of P2X7R antagonists are 292 
well documented [85]. Down regulation of P2X7Rs with siRNA or BBG prevented 293 
the induction of spinal long-term potentiation in vitro and at the same time 294 
alleviated mechanical allodynia in naive rats in vivo [39].  Central sensitization of 295 
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nociceptive neurons could be produced by intrathecal superfusion of Bz-ATP and 296 
was depressed by P2X7R antagonists [86].  Additional studies extended these 297 
findings to mechanisms participating in the development of neuropathic or 298 
orofacial pain [87-89], bone cancer pain [90] and migraine [91]. Recent studies 299 
highlighted the association between human P2X7R variants with chronic pain 300 
sensitivity [24]. 301 
   Multiple sclerosis (MS) is a chronic degenerative disease of the CNS that is 302 
characterized by focal lesions with inflammation, infiltration of immune cells, 303 
demyelination, oligodendroglial death and axonal damage [92]. A putative 304 
association of the P2X7R gene with this illness was indicated by the most 305 
frequent expression of the gain-of-function T allele of rs17525809 polymorphism 306 
of the receptor, which yields an Ala-76 to Val change in its extracellular domain 307 
[93]. The overexpression of P2X7Rs was detected in experimental autoimmune 308 
encephalomyelitis (EAE), an animal model of SM [94], whereas the amelioration 309 
of EAE was found in P2X7R deficient animals [95, 96], but see [97]. Further, 310 
pannexin-1 knockout mice with restricted ability to mediate pore development/dye 311 
uptake after P2X7R stimulation, also displayed a delayed onset of clinical signs 312 
of EAE and decreased mortality when compared with wild-type mice [98]. 313 
    Amyotrophic lateral sclerosis (ALS) is characterized by the progressive 314 
degeneration of motor neurons in the spinal cord, brainstem and motor cortex, 315 
leading to respiratory failure and death of the affected patients within a few years 316 
of diagnosis [99]. Microglia and astrocytes are major contributors to motor neuron 317 
dysfunction in ALS through the maintenance of a chronic inflammatory response. 318 
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Transgenic mice expressing a mutant protein Cu+/Zn+ superoxide dismutase 319 
SOD1-G93A, which directly enhances the activity of the main reactive oxygen 320 
species producing enzyme in microglia (NADPH oxidase 2; NOX2) is used widely 321 
as a model of ALS [100]. P2X7R activation by BzATP induced the death of motor 322 
neurons in mixed astrocytic/neuronal cultures prepared from wild-type mice [101]. 323 
Further, apyrase, an enzyme degrading ATP or BzATP, decreased neuronal 324 
death observed in cultures prepared from SOD-G93A spinal cord. Bz-ATP also 325 
increased the activity of NOX2, leading to motor neuron damage, an effect which  326 
did not occur in primary microglia cultures of SOD-G93A mice lacking P2X7Rs 327 
[102]. 328 
    A neuropathological hallmark of Alzheimer’s disease (AD) is the appearance of 329 
plaques consisting of extracellular -amyloid peptide (A) surrounded by reactive 330 
microglial cells [103]. A triggered increases in intracellular Ca2+, ATP release, 331 
IL-1 secretion and plasma membrane permeabilization in microglia from wild-332 
type but not P2X7R-/- mice [104]. These findings and the neuroprotective effects 333 
of BBG against intrahippocampally injected A suggest that A activates a 334 
purinergic autocrine/paracrine stimulatory loop of which the P2X7R is an 335 
obligatory component. In fact, in vivo inhibition of the P2X7R in mice transgenic 336 
for mutant human APP indicated a significant decrease of the number of 337 
hippocampal amyloid plaques [105]. 338 
     Parkinson’s disease (PD) is a motor disease affecting the striatal 339 
dopaminergic system, by damaging dopaminergic neurons in the substantia 340 
nigra. In the disease model induced by unilateral intrastriatal injection of 6-341 
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hydroxydopamine, BBG and A-438079 prevented the ensuing synaptotoxicity, 342 
gliosis and neurotoxicity [106]. In another study, A-438079 prevented the 343 
depletion of striatal dopamine stores by 6-hydroxydopamine treatment, but this 344 
was not associated with a reduction of dopaminergic cell loss [107]. Similarly, the 345 
effects of P2X7R antagonists appeared to depend on the neurotoxin used, 346 
because in MPTP- or rotenone-induced Parkinson models, the genetic deletion of 347 
the P2X7R did not increase survival rates of mice compared to wild-type 348 
counterparts [108]. 349 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative 350 
disorder caused by a triplet repeat expansion coding for a polyglutamine 351 
sequence in the N-terminal region of the huntingtin protein. A higher P2X7R level 352 
was documented by western-blot analysis in the striatum of transgenic mice 353 
models of this disease [109]. In addition, P2X7R antagonists prevented neuronal 354 
apoptosis and attenuated body weight loss and motor-coordination deficits. 355 
 356 
P2X7R as a potential target in psychiatric disorders  357 
 358 
Mood disorders arise from complex interactions between genetic, developmental 359 
and environmental factors [110, 111]. Linkage studies suggested that variations 360 
of the chromosome 12q24.31 containing candidate genes for P2X7R, P2X4R and 361 
calmodulin-dependent protein kinase b (CaMKKb) may be associated with major 362 
depressive, bipolar and anxiety disorders. It has repeatedly been reported that 363 
the NS-SNP rs2230912 coding for the P2X7R-Glu460Arg is associated with 364 
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major depressive disorder [112, 113]. Further, relevant SNP mutations identified 365 
by linkage studies were introduced into the human recombinant P2X7R and were 366 
expressed in human embryonic kidney cells [114]. The measurement of their 367 
functional properties by the patch-clamp technique indicated that some of them, 368 
including Glu460Arg, exhibited a strong impairment of the current response to 369 
ATP, while other mutants demonstrated significant increases in sensitivity. In 370 
contrast, other studies failed to confirm the allelic or genotypic association of 371 
rs2230912 or other SNPs of P2X7R with mood disorders [115, 116]. The reasons 372 
for this discrepancy are presently unknown. Eventually, variations in the P2X7R 373 
gene were described to be associated with cognitive manic symptoms in bipolar 374 
disorders [117], but not in schizophrenia [118]. 375 
Production of TNF- and IL-6 is initiated by the activation of Toll-like receptors 376 
(TLRs) by e.g. bacterial lipopolysaccharide. The formation of IL-1 also requires 377 
TLR4 induction of gene transcription but requires an additional step, the 378 
processing of pro-IL-1 to the mature form of IL-1, which is then released via 379 
NLRP3 referred to as the “inflammasome” [110, 119]. P2X7Rs are indispensable 380 
activators of NLRP3. Inflammatory cytokines have been suggested to play key 381 
roles in the development of depressive behavior. Their levels are elevated in 382 
depressed patients [110, 120] and rodents exposed to stressful stimuli [111]. 383 
These cytokines are potent activators of the hypothalamic-pituitary-adrenal axis 384 
through which the secretion of hypothalamic corticotropin releasing hormone 385 
(CRH), pituitary adrenocorticotropic hormone (ACTH) and corticosterone are 386 
stimulated. In this respect it is interesting to note that P2X7R stimulation also 387 
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directly leads to increased ACTH secretion from the terminals of hypothalamic 388 
magnocellular neurons [121].  389 
The interrelationship between inflammatory cytokines, P2X7Rs and mood 390 
related behavior has been intensively studied in animal models. The genetic 391 
deletion of P2X7Rs resulted in antidepressive-like behavior in the forced swim 392 
and tail suspension tests and alleviated amphetamine induced hyperactivity   [40, 393 
41]. Although P2X7Rs are present at peripheral/central immunocytes, glial cells 394 
and neurons, it was shown that macrophages and microglia are not responsible 395 
for the detected changes in mood measured by tail suspension test and 396 
amphetamine-induced hyperlocomotion in P2X7R-/- mice [41]. On a larger scale, 397 
several potential mechanisms were identified for the antidepressant phenotype of 398 
P2X7R-/- mice, such as the absence of P2X7R-mediated glutamate release, 399 
elevated basal brain-derived neurotrophic factor (BDNF) production, enhanced 400 
neurogenesis and increased serotonin bioavailability in the hippocampus [48]. It 401 
has also been observed that P2X7Rs are downregulated in the hippocampus in 402 
response to chronic stress [122] and P2X7R-/- mice exhibited impaired adaptive 403 
coping responses to repeated stress [123], which enlighten the potential role of 404 
P2X7Rs as a protective adaptive mechanism in the process leading to mood 405 
disorders.  406 
The above data illustrate that P2X7R seems to be activated in a number of 407 
different pathological conditions raising the possibility that the receptor is one 408 
common avenue of cellular stress signaling pathways (Figure 2). However, one 409 
should keep in mind that the pathophysiology of CNS diseases is very complex 410 
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involving a multiplicity of mediators and signaling pathways and the P2X7R is 411 
only one among the multiple signaling pathways activated. Moreover, the 412 
significance of this avenue is probably not uniform in all CNS pathologies and 413 
could be more prominent in certain disease conditions (e.g. chronic pain, status 414 
epilepticus) than in other ones (e.g. Parkinson’s disease), depending on the 415 
expression of P2X7Rs in the brain area afflicted. Finally, important physiological 416 
functions mediated by P2X7Rs should not be neglected. For instance, taking into 417 
account that the purportedly necrotic/apoptotic P2X7Rs also convey trophic and 418 
adaptive changes, their role might vary or even reverse during the course of the 419 
same disease, because neuroinflammation, regulated by P2X7Rs has also a 420 
double-faced role. In fact, inflammation initially is a protective reaction and 421 
becomes detrimental only, when it progresses to an excessive or chronic phase. 422 
These aspects serve as explanations to conflicting results with P2X7R inhibition 423 
on the disease outcome (e.g. [95-97]) and should also be addressed when 424 
P2X7R is considered as a potential human drug-target. 425 
 426 
 427 
Current development of P2X7R ligands     428 
 429 
Although end-products of the pioneering developments of P2X7R antagonists, 430 
such as CE-224,535 [124] and AZD 9056 [125] have not proved efficacious in 431 
Phase II trials in rheumatoid arthritis patients, clinical studies revealed an 432 
acceptable safety and tolerability profile of such antagonists as a whole [124-433 
20 
 
126], opening up the possibility  of developing P2X7R-targeting compounds in 434 
new areas, such as CNS disorders.  435 
   In recent years, a number of different classes of small molecular weight, drug-436 
like P2X7R ligands have been developed (Table 2), and P2X7Rs have been 437 
qualified as the most “druggable” target within the P2X receptor family [85, 127].  438 
More recently, the development of centrally penetrating potent P2X7R 439 
antagonists has also been reported (Table 2). In addition, systematic search 440 
through compound libraries resulted in the further discovery of novel P2X7R 441 
antagonists and allosteric modulators utilizable either for basic research or drug 442 
development. Analyses of natural compounds have also resulted in several 443 
valuable P2X7R ligands (Table 2). 444 
 445 
 Concluding remarks 446 
 447 
In conclusion, P2X7R mediated pathways appears to be a common avenue  of 448 
many CNS disorders of different aetiology and  P2X7R antagonists are potential 449 
drugs to treat them. Their immense advantage may lie in the absence or low 450 
density of P2X7Rs in healthy tissue and therefore in the limited systemic side 451 
effects of these compounds. However, major caveats in our understanding of the 452 
physiopathological functions of central P2X7Rs should be further elucidated (Box 453 
2). Though the majority of known antagonists fail to pass the blood-brain barrier, 454 
BBG and some new and high affinity P2X7R antagonists readily enter the CNS 455 
[128]. Further, recently identified negative allosteric modulators of P2X7Rs (e.g. 456 
21 
 
certain phenothiazine-type antipsychotic drugs), already registered for human 457 
use [129], may become important therapeutic tools.  458 
   The future development of new P2X7R antagonists has to take into 459 
consideration that P2X7R isoforms may exhibit large variability between different 460 
species in their agonist/antagonist sensitivities. Therefore, the classic search for 461 
new pharmacologically active compounds based on the use of laboratory 462 
animals, may lead to spurious negative or positive results. A further complicating 463 
factor is the presence of numerous splice variants and SNPs widely distributed in 464 
the animal and human organism; their sensitivities to pharmacological blockade 465 
is often different from that of the wild-type receptor. Hence, the development of 466 
new and therapeutically valuable P2X7R antagonists is a tedious task but the 467 
reward may be enormous.  468 
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Box 1.  Tools to study P2X7 receptors  906 
 907 
The continuously evolving interest in this receptor resulted in the generation 908 
of various tools to study its function. P2X7Rs could be identified based on 909 
the following distinctive pharmacological features: 910 
 The affinity of the endogenous agonist ATP is low, in the high micromolar-911 
millimolar range. 912 
 BzATP is a more potent agonist than ATP itself. It has been frequently 913 
used mistakenly as a selective agonist of P2X7R. This is, however, not 914 
valid, because BzATP also binds to other P2X receptors with high affinity.  915 
 The effect of ATP and BzATP are potentiated by a low Ca2+/no Mg2+-916 
containing external medium.  917 
 There are several potent antagonists available, such as A-438079, A-918 
740003, the negative allosteric modulator AZ-10606120 and Brilliant blue 919 
G (BBG); among them BBG is selective in concentrations below 1 µM.    920 
This antagonist is also a useful tool in in vivo experiments. The 921 
penetration of BBG through the blood-brain barrier has already been 922 
determined and using doses not higher than 50 mg/kg, the resultant brain 923 
concentration remains below 1 µM [105]. It should be noted, however, 924 
that many P2X7R antagonists, including BBG also inhibit Panx1 925 
channels. Therefore, BBG alone is inadequate to prove the involvement 926 
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of P2X7Rs [130]. In this respect, a valuable compound could be Brilliant 927 
blue FCF, which inhibits Panx1, but not P2X7R [131]. 928 
 Novel radioligands, i.e. [³H]A-804598 are also available to characterize 929 
the affinity of newly developed compounds to rodent P2X7Rs [25].  930 
In addition to pharmacological approaches, 931 
 genetic knock-down by siRNA has been increasingly used to silence 932 
P2X7Rs in the past years in both in vitro and in vivo studies (e.g. [34, 39]).  933 
 Mouse lines, genetically deficient in P2X7Rs, initially generated by the 934 
companies Glaxo (LacZ gene and neomycin cassette insertion into exon 935 
1; [132]) and Pfizer (Neo insertion in exon 13, close to the carboxyl 936 
terminal; [133]), have also been widely used. However, none of these 937 
mouse lines could be regarded as fully deficient in P2X7Rs, as individual 938 
splice variants evaded inactivation [11, 12].  939 
 For studies of P2X7R function in morphologically identified neurons, 940 
astrocytes or microglia, the GFP-P2X7 reporter mouse seems to be a 941 
crucial tool [134].  942 
 943 
  944 
43 
 
Box 2. Outstanding Questions  945 
 946 
Despite the large interest in P2X7Rs and the correspondingly high number of 947 
publications dealing with this receptor, many questions still remain unresolved. 948 
 The C-terminus of the P2X7R has been implicated in regulating receptor 949 
function including signaling pathway activation, cellular localization, protein-950 
protein interactions, and post-translational modification [135]. It would be 951 
important to learn the three-dimensional structure of the P2X7R C-terminal 952 
tail, which is yet to be determined [4].  953 
 Although repetitive or long-lasting stimulation of P2X7Rs by ATP allows the 954 
passage of 600-800 Da organic molecules through the cell membrane, the 955 
mechanism of pore opening is still a matter of debate. There are good 956 
arguments favouring an accessory protein, with Panx1-hemichannels 957 
probably involved in this effect, but the cationic channel-dilation theory is also 958 
an attractive alternative. 959 
 Original work based on co-immunoprecipitation with epitope tagged subunits 960 
demonstrated that overexpressed recombinant P2X1-6 subunits could form 961 
hetero-oligomeric complexes, while P2X7 was able to form only homomeric 962 
receptor channels [136]. However, it remains to be established whether true 963 
functional P2X4/7 heteromers are formed in native systems, which might have 964 
great significance for CNS immune functions e.g. in microglia.  965 
 A lot of controversy has arisen on the issue of whether P2X7Rs are located 966 
exclusively at microglia and astroglia in the CNS or also at neurons (see the 967 
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discussion on “Tissue and cell type specific distribution of P2X7Rs”). The 968 
solution of this enigma might be that under normal conditions P2X7Rs are 969 
dormant but after various types of damaging conditions (mechanical trauma, 970 
ischemia, inflammation, etc.) they become unmasked, mostly at central 971 
immunocytes but probably also at neurons. Already the tissue damage 972 
afflicted to cells during the culturing procedure or the preparation of brain 973 
slices may be sufficient to induce the expression of previously absent 974 
P2X7Rs. 975 
 Although endogenous activation of P2X7Rs under disease conditions has 976 
repeatedly been proven, its exact mechanism is not fully understood, given 977 
the low affinity of ATP. The possibility of constitutive activity of this receptor as 978 
well as its potential endogenous ligands other than ATP should be explored. 979 
 Whereas available gene deficient  mouse models are not fully deficient in 980 
P2X7Rs, more advanced mouse models, such as cell-type specific and/or 981 
inducible knockouts, optogenetic constructs, as well as humanized mouse 982 
models reproducing human gene polymorphisms in rodents are yet to be 983 
generated for probing P2X7R function.  984 
 985 




Table 1. Examples from recent studies verifying functional P2X7Rs on different 988 
cell types of the rodent central nervous system.  989 















Caudal brainstem, nerve 
terminals 
neurochemistry [139] 










Ca2+ imaging [140] 
Embryonic spinal cord, cultured 
neurons 
neurochemistry [141] 




Cortex, in situ patch clamp 
electrophysiology 
[143] 
Cortex, cultured patch clamp 
electrophysiology 
[144] 
Cerebellum, cultured neurochemistry [145] 
Human, cultured Ca2+ fluorimetry [146] 
Bergmann glia 










Cortex, in situ patch clamp 
electrophysiology 
[149] 
N9 microglia, cultured neurochemistry [150] 
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Table 2. Non-comprehensive list of different classes of P2X7 receptor 992 
antagonists and allosteric modulators. For more information see [151] 993 
 994 
Class/Compound Function Refs 
Novel, small molecule 
 (1H-pyrazol-4-yl) 
acetamides 
antagonist [152, 153] 








Novel, small molecule, CNS active 
JNJ-47965567 antagonist [128] 
polycyclic carboranes antagonist [158] 
Identified by screening compound libraries 














teniposide antagonist [161] 
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Figure Legends 997 
 998 
Figure 1. The simplified schematic structure of the P2X7R in open state (A) and 999 
during pore formation (B and C). The P2X7R functions as a homo-trimer, forming 1000 
a chalice-like structure, while the individual P2X7R subunit is akin to a leaping 1001 
dolphin. The agonist binding sites are located at the subunit interfaces and the 1002 
occupation of two out of three binding sites is necessary for opening of the 1003 
channel. In addition to ATP, which is the presumed endogenous agonist, the 1004 
mouse P2X7R receptor could also be activated by NAD+ through ADP-1005 
ribosylation. The activation of the receptor-ion channel leads to the inward flux of 1006 
cationic current.  Prolonged and /or repeated activation of P2X7R and occupation 1007 
of the third agonist binding site renders the membrane permeable for high 1008 
molecular weight organic cations and dyes such as NMDG+ and Yo-Pro-1+ (B 1009 
and C). B. One potential mechanism of the pore formation is the dilation of the 1010 
P2X7R-mediated channel pore itself. C. Alternatively, but not exclusively, 1011 
additional pore forming proteins, such as pannexin (Panx1) might be recruited, 1012 
which seem to be indispensable for pore formation under certain circumstances.  1013 
 1014 
 1015 
Figure 2. Common disease mechanism by P2X7R mediated pathways in CNS 1016 
disorders of different etiology. P2X7 receptors are expressed on nerve terminals, 1017 
astrocytes and microglia and they are upregulated upon various disease 1018 
conditions. Stress signals, such as hypoxia/ischemia (metabolic limitations), 1019 
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mechanical injury, and bacterial or chemical toxins elicit the endogenous 1020 
activation of P2X7R and leads to a self-amplifying ATP release and to further 1021 
activation of P2X7 receptors on neighbouring cells.  Following the influx of Ca2+ 1022 
through the receptor ion channel complex, P2X7 receptor activation (a) releases 1023 
glutamate from nerve terminals and astrocytes by both exocytotic and non-1024 
exocytotic mechanisms, which may give rise excitotoxicity; (b)  leads to the 1025 
posttranslational processing of pro-IL-1 to the leaderless, mature IL- and to its 1026 
further release by the NLRP3 inflammasome and that of other cytokines, which 1027 
contribute to neuroinflammation; (c) enhance ROS production and thereby 1028 
aggravate protein  misfolding and neuronal damage;  (d) leads directly or 1029 
indirectly to cell death and the following reactive astrogliosis (e) directly or 1030 
indirectly downregulates the production of BDNF and the following 1031 
neuroplasticity. These key mechanisms could be manifested and contribute to 1032 
disease pathology in Alzheimer’s disease (AD), Parkinson’s disease (PD), 1033 
Huntington’s disease (HD), status epilepticus (SE), amyotrophic lateral sclerosis 1034 
(ALS), multiple sclerosis (MS), stroke, pain and mood disorders in different forms 1035 
and proportion, depending on the etiology.  GLU, glutamate, ROS, reactive 1036 
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